XZB-0004, developed by Xuanzhu Biopharmaceutical Co., Ltd., is positioned to address the significant unmet medical need in relapsed/refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). The global market for AML therapies is projected to grow substantially, driven by increasing incidence rates and advancements in treatment options. The competitive landscape includes established therapies and emerging agents targeting similar pathways. Successful outcomes from this trial could enhance Xuanzhu's market position and attract potential partnerships or acquisitions, given the high-value nature of oncology assets. Diligence should focus on the robustness of the clinical data, regulatory pathways, and potential market access strategies.